ArticleJournal of the American Heart Association2026
Monosialoganglioside-Containing Nanoliposomes Protect Against Acute and Chronic Ischemic Stroke Injury.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundNeuroprotective strategies as primary or ancillary treatment could ameliorate the significant mortality and disability associated with ischemic stroke. Nanoliposomes composed of monosialoganglioside, phosphatidylcholine, and cholesterol (NLGM1) were previously shown to ameliorate brain injury when given before arterial occlusion in mice. We aimed to test the hypothesis that NLGM1 given following transient intraluminal filament and photothrombotic (PT) middle cerebral artery occlusion (MCAO) will attenuate acute and chronic stroke injury in mice.
methodsTwelve-week-old C57BL/6 mice underwent MCAO for 45 minutes and were then injected with 1 or 3 doses of saline or NLGM1 (1 or 2 mg IV) after occlusion. Neurologic deficit score and brain infarct area were measured after 48 hours. Separate mice underwent PT occlusion of the distal lateral middle cerebral artery trunk followed by injection of 1 or 2 doses saline or NLGM1 (1 or 2 mg IV) postocclusion. Motor and behavior testing was performed at 21, 30, 45, and 90 days after PT MCAO.
resultsFollowing intraluminal MCAO, single-dose NLGM1-treated mice exhibited reduced neurological impairment (neurologic deficit score 3.6±0.2, 2.6±0.3, 2.4±0.3 at 0, 1, 2 mg, respectively;
conclusionsTreatment of mice with NLGM1 resulted in reduced brain infarct size acutely following intraluminal MCAO and improved motor and behavior function acutely and chronically following intraluminal and PT MCAO. NLGM1 represents a promising novel neuroprotective agent in stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.